As of 2024-12-13, the EV/EBITDA ratio of Medipharm Labs Corp (LABS.TO) is -1.15. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. LABS.TO's latest enterprise value is 14.28 mil CAD. LABS.TO's TTM EBITDA according to its financial statements is -12.42 mil CAD. Dividing these 2 quantities gives us the above LABS.TO EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.8x - 10.2x | 7.9x |
| Forward P/E multiples | 15.3x - 26.3x | 17.7x |
| Fair Price | (0.43) - (0.28) | (0.36) |
| Upside | -765.6% - -528.5% | -648.5% |
| Date | EV/EBITDA |
| 2024-12-10 | -1.15 |
| 2024-12-09 | -1.15 |
| 2024-12-06 | -1.32 |
| 2024-12-05 | -1.15 |
| 2024-12-04 | -1.32 |
| 2024-12-03 | -1.15 |
| 2024-12-02 | -1.15 |
| 2024-11-29 | -1.32 |
| 2024-11-28 | -1.15 |
| 2024-11-27 | -1.15 |
| 2024-11-26 | -1.15 |
| 2024-11-25 | -1.32 |
| 2024-11-22 | -1.15 |
| 2024-11-21 | -1.32 |
| 2024-11-20 | -1.32 |
| 2024-11-19 | -1.32 |
| 2024-11-18 | -1.32 |
| 2024-11-15 | -1.32 |
| 2024-11-14 | -1.32 |
| 2024-11-13 | -1.65 |
| 2024-11-12 | -1.48 |
| 2024-11-11 | -1.15 |
| 2024-11-08 | -1.32 |
| 2024-11-07 | -1.32 |
| 2024-11-06 | -1.32 |
| 2024-11-05 | -1.32 |
| 2024-11-04 | -1.32 |
| 2024-11-01 | -1.32 |
| 2024-10-31 | -1.32 |
| 2024-10-30 | -1.32 |
| 2024-10-29 | -1.48 |
| 2024-10-28 | -1.48 |
| 2024-10-25 | -1.48 |
| 2024-10-24 | -1.48 |
| 2024-10-23 | -1.65 |
| 2024-10-22 | -1.48 |
| 2024-10-21 | -1.65 |
| 2024-10-18 | -1.48 |
| 2024-10-17 | -1.48 |
| 2024-10-16 | -1.48 |
| 2024-10-15 | -1.32 |
| 2024-10-11 | -1.32 |
| 2024-10-10 | -1.48 |
| 2024-10-09 | -1.32 |
| 2024-10-08 | -1.32 |
| 2024-10-07 | -1.32 |
| 2024-10-04 | -1.32 |
| 2024-10-03 | -1.15 |
| 2024-10-02 | -1.15 |
| 2024-10-01 | -1.32 |